Thanks for sharing mate.

First 20 Last

Share
Profile

Follow
NC1977

73 Posts.

12

16/05/19

13:48

Post #: 38595855
Share

Originally posted by throwerw: ↑

The Queensland Investment Club seemed to be mostly retiree retail investors, but sophisticated investors for sure with plenty of collective experience and capital. Geoff and Rade gave solid presentations. Several shareholders were in attendance and I think that must have made a good impression. Later throughout the night I did hear rumblings about ANO looking like a good punt. A few interesting bits of information:

BASF alone has a EUR700 million UV chemical business that is "up for grabs"

ANO product has superior transparency to other zinc oxide

Gold works well for blocking UV but is a bit too expensive for that purpose

Titanium dioxide only covers UVB and requires chemicals to cover broad spectrum, so whats the point?

Quality control is a top priority. Every batch of precursor is tested for heavy metal content and every batch of finished product is tested for SPF. Customers place an emphasis on consistency of quality and are unlikely to reformulate as long as they can get that. SPF scandal can put a small brand out of business.

Chemical UV inhibitors were not originally intended for high frequency use, consumer behavior and needs have changed to apply much more frequently.

The harder they work the luckier they get. Geoff is now prioritizing growth in Europe, which only approved nano zinc oxide in 2016.

Corporate culture was rebuilt from the ground up after the change in control. 15 out of 16 employees in Perth were let go and 7 were hired to right size the business and get the culture right. That culture seems to be laser focused on activities that build shareholder value.

Estee Lauder and Clinique are known customers, the rest is largely a secret held by distributors.

California expected to ban chemical sunscreen later this year. Australia will hopefully soon follow.

Rade would like Brian's junk to be worth a billion dollars.

Expand

Thanks for sharing mate.

Last edited by NC1977: 16/05/19

ANO Price at posting: $4.74 Sentiment: None Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

OJC

SPC to merge with Original Juice Co and Nature One Dairy

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 16 more messages in this thread...

First 20 Last

Add ANO (ASX) to my watchlist

(20min delay)
Last 77.0¢		Change 0.010(1.32%)		Mkt cap ! $48.08M

Open	High	Low	Value	Volume
77.5¢	77.5¢	77.0¢	$3.292K	4.272K

Buyers (Bids)

No.	Vol.	Price($)
1	5273	77.0¢

Sellers (Offers)

Price($)	Vol.	No.
90.0¢	5250	2

View Market Depth

No.	Vol.	Price($)
1	5273	0.770
1	49122	0.760
1	24	0.730
1	42952	0.720
1	714	0.700

Price($)	Vol.	No.
0.900	5250	2
0.950	5000	1
1.000	11450	2
1.050	5000	1
0.000	0	0

Last trade - 16.10pm 02/10/2024 (20 minute delay)

ANO (ASX) Chart

Thanks for sharing mate.

SPC to merge with Original Juice Co and Nature One Dairy

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thanks for sharing mate.

Top Stories

SPC to merge with Original Juice Co and Nature One Dairy

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News